IRG Research Introduces the First Source of Weekly Oncology Prescription Data for Investors
IRG Research, the independent equity research firm and securities broker-dealer, through its healthcare alliance partner MDRx Financial, today introduced a proprietary weekly oncology prescription data source -- the largest available to the financial community -- to help institutional investors make better decisions in the biotechnology sector.
New York, NY (PRWEB via PR Web
Direct) April 6, 2005 -- IRG Research, the independent equity research firm
and securities broker-dealer, through its healthcare alliance partner MDRx
Financial, today introduced a proprietary weekly oncology prescription data
source -- the largest available to the financial community -- to help
institutional investors make better decisions in the biotechnology
sector.
The IRG/MDRx prescription data source expands on IRG/MDRx's
ability to give institutional investors a unique source of healthcare
intelligence through proprietary retail pharmacy, biotech and pharmacy
prescription databases along with access to top doctors in America and a network
of leading pharmacists and distributors.
The proprietary IRG/MDRx
oncology data source tracks the prescriptions of more than 500 high-prescribing
U.S. oncologists nationwide, representing approximately 5% of the $32 billion
U.S. oncology market -- the first time this level of information has been
available to investors.
"With the IRG/MDRx oncology data source, our
institutional investor clients will now have an in-depth look at prescription
trend changes weeks ahead of any other information source on the market," said
Joseph C. Marino, managing director and chief operating officer of IRG
Research.
"These oncology drugs are not sold in pharmacies, but are
infused at the oncologist's practice. So for investors to know what's happening
in hundreds of oncologists' offices on a weekly basis is a remarkable thing,"
said Keith Pride, partner and co-founder of MDRxFinancial.
The IRG/MDRx
resource's fully-dynamic interface allows investors to analyze drugs by
prescription, by price, by company, and even by the diseases each drug treats,
said Pride.
About IRG Research
IRG Research is a registered
broker-dealer created to provide institutional and hedge fund money managers
with unbiased and differentiated equity research. IRG's top-tier industry
analysts provide in-depth, action-oriented investment ideas without the
conflicts created by investment banking, underwriting, and proprietary trading.
Analysts concentrate on uncovered and under-covered stocks and have a small to
mid-cap focus. Sector coverage includes Aerospace & Defense, Biotech,
Communications Equipment; Communications Services & Infrastructure; Energy;
Financial Services; Leisure, Graphics & Imaging; Satellite, Cable &
Broadcasting; Specialty Retail - Softlines; Specialty Retail - Hardlines and
Technology. IRG also provides clients direct and unfiltered access to key
industry participants, management teams, and thought leaders through its IRG
Institutional Marketing Group. IRG Research is a wholly owned subsidiary of
TheStreet.com (NASDAQ: TSCM). Additional information about IRG Research can be
found at www.irgresearch.com.
Statements contained in this news
release not related to historical facts may be deemed forward-looking statements
as that term is defined in the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements are subject to risks and uncertainties
(described in the Company's SEC filings), which could cause actual results to
differ.
About MDRxFinancial
MDRxFinancial was founded in 2002 to
provide independent research on the healthcare industry. MDRxFinancial combines
unique sources of data and industry experts to deliver a comprehensive and
dynamic view of the health care marketplace. In conjunction with its strategic
partner, Castle Connolly Medical, MDRx has created a network of 5,000 top
board-certified physician specialists in America, representing the finest
medical centers and research hospitals. MDRx also has two proprietary
prescription databases that will be available to IRG clients. The first is a
retail prescription and pricing database from over 3,000 independent pharmacies
and wholesalers across the US. This data is available days ahead of the other
leading sources of pharmaceutical information used by the investment community.
The second is an oncology product database that reflects 10% of total oncology
drug-related sales in the US. MDRx's proprietary online pharmaceutical sales
data engine provides fully dynamic views of any of the 40,000 prescription drugs
sold in the US. In addition to the network and databases from MDRx, IRG expects
to provide access to board-certified pharmacists for phone consultation and
surveys. Additional information about MDRXFinancial can be found at www.mdrxfinancial.com.
Contacts:
Wendy Marx
Marx Communications
203-445-2850
e-mail
protected from spam bots
Tom Mariam
Marx
Communications
914-939-4294
e-mail protected from spam bots
# #
#
Source : http://www.prweb.com/releases/2005/4/prweb226265.htm